Once-daily Biktarvy, long-acting injectable Cabenuva and two-drug combos containing dolutegravir can keep HIV in check for years.

The all-oral regimen maintained viral suppression in people with resistance to multiple antiretrovirals.

People treated with Biktarvy were more likely to achieve an undetectable HBV viral load than those on a dolutegravir-based regimen.

Disruption of fat metabolism and altered gut microbiome may help explain weight changes associated with antiretroviral therapy.

People starting on integrase inhibitors were no more likely to have heart attacks, strokes or cardiovascular procedures.

People who saw substantial CD4 T-cell gains during the first two years after diagnosis had better outcomes.

Once-daily pill suppressed HBV viral load in nearly two thirds of people with HIV/HBV coinfection.

In January, Gilead Sciences claimed that over $250 million in counterfeit meds were sold and that it had sued the illegal distributors.

Biktarvy is now available for small children.